New research indicates that patients hospitalized with active cancer were more likely to die from COVID-19 than those with a history of cancer or those without any cancer diagnosis. The findings published by Wiley early online in CANCER, a peer-reviewed journal of the American Cancer Society, also indicate those with active blood cancers have the greatest risk of death due to COVID-19.
Agendia, Inc., a world leader in precision oncology for breast cancer, announced that new data from the first-of-its kind, national FLEX registry was debuted today at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
(0)
Whole transcriptome analysis of ER+ breast cancers showed no substantial difference in gene expression between tumors from women younger than 50 and women older than 50
Whole transcriptome analysis confirms that genomic expression profiles from BluePrint ER+ Basal tumors and ER- Basal tumors are very similar, providing clinically actionable information to guide neoadjuvant treatment decisions
FLEX real-world registry to enroll 10,000 patients with breast cancer by end of 2021, with ultimate goal to enroll 30,000 total Agendia, Inc., a world leader in precision oncology for breast cancer, announced that new data from the first-of-its kind, national FLEX registry was debuted today at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
The new drug sotorasib reduces tumor size and shows promise in improving survival among patients with lung tumors caused by a specific DNA mutation, according to results of a global phase 2 clinical trial led by Washington University School of Medicine in St. Louis. The drug is designed to shut down the effects of the mutation, which is found in about 13% of patients with lung adenocarcinoma, a common type of non-small-cell lung cancer.
/PRNewswire/ A new drug reduced tumor size in patients who have lung cancer patients with a specific, disease-causing change in the gene KRAS, a study found..